HCMV Laboratory and Clinical Strains Suppress Monocyte Oxidative Activity
| . | Multiplicity of Infection (MOI) Equivalent (%) . | ||
|---|---|---|---|
| . | 0.02 . | 0.002 . | 0.0002 . |
| Laboratory strains | |||
| AD169 | 29.6 ± 6.1 | −2.3 ± 5.1 | 3.0 ± 4.1 |
| Towne | 44.8 ± 6.2 | 21.9 ± 9.1 | 3.1 ± 6.6 |
| Toledo | 43.4 ± 3.0 | 42.4 ± 2.8 | 21.6 ± 5.6 |
| Clinical strain | |||
| Hei | ND | 42.5 ± 4.1 | 12.1 ± 3.2 |
| . | Multiplicity of Infection (MOI) Equivalent (%) . | ||
|---|---|---|---|
| . | 0.02 . | 0.002 . | 0.0002 . |
| Laboratory strains | |||
| AD169 | 29.6 ± 6.1 | −2.3 ± 5.1 | 3.0 ± 4.1 |
| Towne | 44.8 ± 6.2 | 21.9 ± 9.1 | 3.1 ± 6.6 |
| Toledo | 43.4 ± 3.0 | 42.4 ± 2.8 | 21.6 ± 5.6 |
| Clinical strain | |||
| Hei | ND | 42.5 ± 4.1 | 12.1 ± 3.2 |
Monocyte oxidative activities were compared between PBMC incubated with different strains of inactivated HCMV at different MOI equivalents (see legend to Fig 1). Assays were performed in triplicate at day 4. Results are presented as the percentage of inhibition (mean ± SD) corresponding to the ratio between the mean of the OD values obtained with HCMV and the mock preparation multiplied by 100.